Saturday 17 October 2026
Export TARS’s income statement to Excel — free account
Tarsus Pharmaceuticals, Inc.
TARS Healthcare Biotechnology
Tarsus Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $451.4 million, up 146.7% from fiscal 2024. In the quarter to June 2026, revenue grew 69.4%, EPS grew 10.4%, free cash flow grew 288.1% and total debt was flat, each against the same quarter a year earlier.
68.07
2.92
−4.11%
Follow TARS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
4.50 | 5.63 | 7.58 | 6.92 | |
P/FCF ratio |
58.11 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
44.61 | (122.24) | 176.99 | 138.70 | |
P/B ratio |
7.88 | 8.64 | 9.96 | 7.56 | |
Price to Tangible BV |
8.04 | 8.82 | 10.18 | 7.73 | |
EV/Sales |
3.88 | 5.04 | 6.81 | 6.02 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
31.75 | (163.95) | (247.04) | (40.82) | |
EV/FCF |
50.09 | (66.54) | (98.24) | (33.10) | |
Quick Ratio |
3.12 | 3.53 | 3.72 | 4.07 | |
Current Ratio |
3.20 | 3.74 | 3.85 | 4.29 | |
Net Debt/EBITDA |
19.33 | 49.59 | 41.60 | 21.33 | |
Debt/Assets |
11.91% | 12.49% | 12.89% | 13.52% | |
Debt/Equity |
0.21 | 0.21 | 0.21 | 0.22 | |
Asset Turnover |
1.10 | 0.99 | 0.96 | 0.80 | |
Operating CF/Net income |
(3.30) | 3.54 | (2.31) | (1.45) | |
Capex/Depreciation |
(10.07) | 23.00 | 19.50 | 2.07 | |
Interest Coverage |
(9.23) | (2.88) | (3.60) | (6.41) | |
Research and Development Expense of Revenue |
17.83% | 13.79% | 11.89% | 13.72% | |
Selling, General and Administrative Expense of Revenue |
86.65% | 84.19% | 86.16% | 91.52% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
7.64% | 7.38% | 9.44% | 10.31% | |
Graham Net Nets |
0.11 | 0.10 | 0.09 | 0.12 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(1.73%) | (1.63%) | (1.98%) | (3.40%) | |
Free Cash Flow Yield |
1.72% | (1.35%) | (0.92%) | (2.63%) | |
Revenue per Share |
4.01 | 3.77 | 3.63 | 2.79 | |
Operating CF per Share |
1.41 | (0.57) | 0.46 | 0.43 | |
Capex per Share |
(0.09) | (0.14) | (0.15) | (0.04) | |
Free Cash Flow per Share |
1.32 | (0.71) | 0.31 | 0.38 | |
Cash per Share |
10.36 | 9.05 | 10.00 | 9.43 | |
Shareholders Equity per Share |
7.99 | 8.12 | 8.22 | 7.86 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.99 | 8.12 | 8.22 | 7.86 | |
Free Cash Flow |
57.15 | (30.47) | 12.97 | 16.35 | |
Working Capital |
386.24 | 393.72 | 387.09 | 384.65 | |
Capital Expenditures |
(4.07) | (5.82) | (6.36) | (1.91) | |
Net Current Asset Value |
297.58 | 305.05 | 304.05 | 302.23 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.04 | 0.04 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
79.27 | 90.68 | 67.58 | 52.32 | |
Average Payables |
59.39 | 50.25 | 12.90 | 79.02 | |
Average Inventory |
4.13 | 3.64 | 3.50 | 3.34 | |
Average Assets |
553.07 | 540.94 | 469.57 | 455.43 | |
Average Common Equity |
339.67 | 345.70 | 283.98 | 286.28 |
Columns are period end dates